{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:55:23Z","timestamp":1776722123176,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.nucmedbio.2010.04.020","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T08:54:58Z","timestamp":1275987298000},"page":"741-750","source":"Crossref","is-referenced-by-count":29,"title":["Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands"],"prefix":"10.1016","volume":"37","author":[{"given":"Marc","family":"Hens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesan","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Guang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darell D.","family":"Bigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2010.04.020_bib1","first-page":"601","article-title":"Radium therapy","volume":"64","author":"Cleaves","year":"1903","journal-title":"Med Rec"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib2","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","article-title":"Tumor therapy with targeted atomic nanogenerators","volume":"294","author":"McDevitt","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/snuc.2001.27043","article-title":"Recent advances in radionuclide therapy","volume":"31","author":"Srivastava","year":"2001","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1053-4296(00)80045-4","article-title":"Clinical radioimmunotherapy","volume":"10","author":"Knox","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3816\/CLM.2000.n.010","article-title":"Are radiometal-labeled antibodies better than iodine-131\u2013labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67\u2013, iodine-131\u2013, and yttrium-90\u2013labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma","volume":"1","author":"DeNardo","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib6","first-page":"302","article-title":"67Cu-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma","volume":"40","author":"DeNardo","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.1996.14.4.1383","article-title":"Radioimmunotherapy: recent results and future directions","volume":"14","author":"Wilder","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/02841869609101651","article-title":"Radioimmunotherapy of solid cancers","volume":"35","author":"Kairemo","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1586\/14737140.7.5.675","article-title":"Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients","volume":"7","author":"Reardon","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/3-540-46009-8_8","article-title":"Fundamentals of receptor-based diagnostic metalloradiopharmaceuticals","volume":"222","author":"Liu","year":"2002","journal-title":"Top Curr Chem"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1021\/bc000070v","article-title":"Bifunctional chelators for target-specific therapeutic lanthanide radiopharmaceuticals","volume":"12","author":"Liu","year":"2001","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004032-195907000-00001","article-title":"Metabolic characteristics within a chemical family","volume":"2","author":"Durbin","year":"1960","journal-title":"Health Phys"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/108497803322287592","article-title":"Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma","volume":"18","author":"Postema","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib15","first-page":"327","article-title":"Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re","volume":"45","author":"Brouwers","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0969-8051(02)00294-9","article-title":"In vivo comparison of monoclonal antibodies with 177Lu for radioimmuno-therapeutic applications","volume":"29","author":"Milenic","year":"2002","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.nucmedbio.2006.11.003","article-title":"Anti-tenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands","volume":"34","author":"Yordanov","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nucmedbio.2008.11.001","article-title":"Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with177Lu: in vitro comparison of acyclic and macrocyclic ligands","volume":"36","author":"Hens","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/bc0001490","article-title":"A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB)","volume":"12","author":"Vaidyanathan","year":"2001","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib20","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1073\/pnas.87.11.4207","article-title":"Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma","volume":"87","author":"Humphrey","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/13550289809114515","article-title":"The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target","volume":"4","author":"Wikstrand","year":"1998","journal-title":"J Neurovirol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib22","first-page":"3140","article-title":"Monoclonal antibodies against EGFRvllI are tumor specific and react with breast and lung carcinomas and malignant gliomas","volume":"55","author":"Wikstrand","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib23","first-page":"4375","article-title":"Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts","volume":"55","author":"Reist","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ange.19760882208","article-title":"Complex formation with tetraazacycloalkane-N, N \u2032, N \u2033, N \u2032\u2033-tetraacetic acids as a function of ring size","volume":"88","author":"Stetter","year":"1976","journal-title":"Angew Chem"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0969-8051(99)00054-2","article-title":"Spectrophotometric method for the determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates","volume":"26","author":"Dadachova","year":"1999","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/bc00016a014","article-title":"Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA\u2013monoclonal antibody conjugates","volume":"3","author":"Pippin","year":"1992","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nprot.2007.20","article-title":"Synthesis of N-succinimidyl 4-guanidinomethyl-3-[\u204eI]iodobenzoate: a radioiodination agent for labeling internalizing proteins and peptides","volume":"2","author":"Vaidyanathan","year":"2007","journal-title":"Nature Protocols"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib28","first-page":"4453","article-title":"Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody","volume":"60","author":"Foulon","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib29","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib30","first-page":"1510","article-title":"Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate","volume":"57","author":"Reist","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nucmedbio.2009.03.006","article-title":"Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation","volume":"36","author":"Koumarianou","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.nucmedbio.2009.05.004","article-title":"177Lu-Labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts","volume":"36","author":"Zacchetti","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2010.04.020_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1021\/bc000070v","article-title":"Bifunctional chelators for target-specific lanthanide radiopharmaceuticals","volume":"12","author":"Liu","year":"2001","journal-title":"Bioconj Chem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805110000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805110000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T22:35:21Z","timestamp":1559169321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805110000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0969805110000892"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2010.04.020","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}